Literature DB >> 9928377

HIV/SIV enteropathy.

M Zeitz1, R Ullrich, T Schneider, S Kewenig, K Hohloch, E O Riecken.   

Abstract

Evidence is increasing that HIV/SIV-induced changes in the highly differentiated gut-associated immune system play a central role in the pathogenesis of gastrointestinal manifestations in HIV/SIV infection. It has been shown in both humans infected with HIV and in nonhuman primates infected with SIV that a rapid, very early, and more pronounced loss of CD4+ T-cells occurs in the mucosa in comparison to the peripheral blood. The loss of this important regulatory T-cell subset might explain mucosal immunodeficiency with the consequence of opportunistic mucosal infections. In addition, there is evidence that small intestinal damage occurs independently of secondary infections (HIV/SIV enteropathy). In late-stage human disease, HIV enteropathy is characterized by villous atrophy with hyporegeneration and dysmaturation of intestinal epithelial cells. In SIV infection of macaques, villous atrophy is a very early event; however, it is accompanied by crypt cell hyperproliferation. Early- and late-stage enteropathy in immunodeficiency virus infection may represent two types of immunologically mediated mucosal transformation in which the number and state of activation of regulatory T cells determine whether hypo- or hyperproliferative villous atrophy occurs.

Entities:  

Mesh:

Year:  1998        PMID: 9928377     DOI: 10.1111/j.1749-6632.1998.tb11118.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

1.  HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report.

Authors:  Brandi Giovanni; Carlo Calabrese; Roberto Manfredi; Anna Maria Pisi; Giulio Di Febo; Rossella Hakim; Giovanna Cenacchi; Guido Biasco
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 2.  An approach to duodenal biopsies.

Authors:  S Serra; P A Jani
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

3.  Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS.

Authors:  Charles R Brown; Meggan Czapiga; Juraj Kabat; Que Dang; Ilnour Ourmanov; Yoshiaki Nishimura; Malcolm A Martin; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

4.  Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques.

Authors:  Suefen Kwa; Sunil Kannanganat; Pragati Nigam; Mariam Siddiqui; Ravi Dyavar Shetty; Wendy Armstrong; Aftab Ansari; Steven E Bosinger; Guido Silvestri; Rama Rao Amara
Journal:  Blood       Date:  2011-06-21       Impact factor: 22.113

5.  HIV and the Gastrointestinal Tract.

Authors:  Nancy F Crum-Cianflone
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2010-09

6.  Marked Enteropathy in an Accelerated Macaque Model of AIDS.

Authors:  Joshua D Croteau; Elizabeth L Engle; Suzanne E Queen; Erin N Shirk; M Christine Zink
Journal:  Am J Pathol       Date:  2017-01-03       Impact factor: 4.307

Review 7.  Th17 cytokines and the gut mucosal barrier.

Authors:  Christoph Blaschitz; Manuela Raffatellu
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

Review 8.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

Review 9.  Advances in sexually transmitted infections of the gastrointestinal tract.

Authors:  Siew C Ng; Brian Gazzard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-25       Impact factor: 46.802

Review 10.  Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.

Authors:  Emily S Ford; Camille E Puronen; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.